NASDAQ:OVID Ovid Therapeutics (OVID) Stock Price, News & Analysis $1.06 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.00▼$1.0650-Day Range$0.70▼$3.2952-Week Range$0.68▼$4.14Volume198,943 shsAverage Volume503,553 shsMarket Capitalization$75.20 millionP/E RatioN/ADividend YieldN/APrice Target$4.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ovid Therapeutics alerts: Email Address Ovid Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside343.4% Upside$4.70 Price TargetShort InterestHealthy1.91% of Float Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.58Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.81) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.78 out of 5 starsMedical Sector47th out of 936 stocksPharmaceutical Preparations Industry15th out of 436 stocks 4.3 Analyst's Opinion Consensus RatingOvid Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageOvid Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ovid Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.91% of the float of Ovid Therapeutics has been sold short.Short Interest Ratio / Days to CoverOvid Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ovid Therapeutics has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOvid Therapeutics does not currently pay a dividend.Dividend GrowthOvid Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOvid Therapeutics has received a 71.15% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for Epilepsy or seizures" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Ovid Therapeutics is -0.85. Previous Next 2.5 News and Social Media Coverage News SentimentOvid Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Ovid Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for OVID on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added Ovid Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ovid Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.30% of the stock of Ovid Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.24% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ovid Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Ovid Therapeutics are expected to grow in the coming year, from ($0.81) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ovid Therapeutics is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ovid Therapeutics is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOvid Therapeutics has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Ovid Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Ovid Therapeutics Stock (NASDAQ:OVID)Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Read More OVID Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OVID Stock News HeadlinesJuly 26 at 6:57 PM | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Ovid Therapeutics (OVID) and Dexcom (DXCM)July 26 at 6:57 PM | markets.businessinsider.comBuy Rating Affirmed for Ovid Therapeutics on Advisory Expansion and Promising Epilepsy Drug ProspectsJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.July 26 at 12:13 PM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDJuly 24 at 8:00 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDJuly 23 at 8:00 AM | globenewswire.comOvid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and EpileptologistsJuly 21, 2024 | americanbankingnews.comOvid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 20, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.July 18, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDJuly 15, 2024 | insidermonkey.comOvid Therapeutics Inc. (OVID): One of the Best Penny Stocks to Buy Under $1 According to Hedge Funds?July 12, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDJuly 10, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDJuly 10, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDJuly 7, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDJuly 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDJuly 1, 2024 | globenewswire.comOvid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous MalformationsJune 30, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDSee More Headlines Receive OVID Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OVID CUSIPN/A CIK1636651 Webwww.ovidrx.com Phone(646) 661-7661FaxN/AEmployees60Year Founded2014Price Target and Rating Average Stock Price Target$4.70 High Stock Price Target$8.00 Low Stock Price Target$1.20 Potential Upside/Downside+343.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,340,000.00 Net Margins-10,691.14% Pretax Margin-10,691.35% Return on Equity-53.62% Return on Assets-37.76% Debt Debt-to-Equity Ratio0.18 Current Ratio10.47 Quick Ratio10.47 Sales & Book Value Annual Sales$390,000.00 Price / Sales192.81 Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book0.85Miscellaneous Outstanding Shares70,940,000Free Float61,509,000Market Cap$75.20 million OptionableOptionable Beta0.44 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Jeremy Max Levin Ba Zoology (Age 71)Dphil, Mb Bchir, President, CEO & Chairman Comp: $1.03MMr. Jeffrey A. Rona (Age 56)Chief Business and Financial Officer Comp: $761.24kMr. Thomas Michael Perone J.D. (Age 59)M.B.A., General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $745.71kMr. Jason Tardio M.B.A. (Age 47)Chief Operating Officer Comp: $652.84kMr. Simon D. Kelner (Age 50)Chief Human Resources Officer Dr. Dirk Haasner (Age 59)Senior Vice President of Global Manufacturing & CMC QA Comp: $416.95kDr. Todd F. Baumgartner M.D.M.P.H., Senior Vice President of Regulatory AffairsDr. Julia Tsai Ph.D. (Age 49)Senior Vice President of Clinical Development Ms. Meg AlexanderChief Strategy OfficerDr. Manoj Malhotra M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsTherapeuticsMDNASDAQ:TXMDImmunicNASDAQ:IMUXFoghorn TherapeuticsNASDAQ:FHTXNektar TherapeuticsNASDAQ:NKTRMersana TherapeuticsNASDAQ:MRSNView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 11,390 shares on 7/26/2024Ownership: 0.308%BVF Inc. ILSold 2,997,233 shares on 5/16/2024Ownership: 5.442%Price T Rowe Associates Inc. MDBought 3,145 shares on 5/15/2024Ownership: 0.025%Vanguard Group Inc.Sold 13,469 shares on 5/10/2024Ownership: 4.203%SG Americas Securities LLCSold 3,854 shares on 5/7/2024Ownership: 0.051%View All Insider TransactionsView All Institutional Transactions OVID Stock Analysis - Frequently Asked Questions How have OVID shares performed this year? Ovid Therapeutics' stock was trading at $3.22 at the beginning of the year. Since then, OVID shares have decreased by 67.1% and is now trading at $1.06. View the best growth stocks for 2024 here. How were Ovid Therapeutics' earnings last quarter? Ovid Therapeutics Inc. (NASDAQ:OVID) announced its earnings results on Tuesday, May, 14th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.06. The company earned $0.15 million during the quarter, compared to analysts' expectations of $0.11 million. Ovid Therapeutics had a negative net margin of 10,691.14% and a negative trailing twelve-month return on equity of 53.62%. When did Ovid Therapeutics IPO? Ovid Therapeutics (OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers. Who are Ovid Therapeutics' major shareholders? Top institutional investors of Ovid Therapeutics include Bank of New York Mellon Corp (0.31%). Insiders that own company stock include Jeremy M Levin and Jason Tardio. View institutional ownership trends. How do I buy shares of Ovid Therapeutics? Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ovid Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP) and SCYNEXIS (SCYX). This page (NASDAQ:OVID) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ovid Stock Alerts